Nutex Health, Inc.
For the period ended Jun 30, 2025. Filed Nov 18, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Nov 18, 2025
NUTX$186.25-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Common Stock · Additional Paid-inCapital · Accumulated Deficit · NoncontrollingInterests · TotalEquity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands, except share data) · Shares · Amount | |||||||||||
| Balance at December 31, 2023 | 4,511,199 | $5 | $470,521 | $(409,073) | $17,652 | $79,105 | |||||
| Common stock issued for Employee Stock Purchase Plan | 746 | — | 19 | — | — | 19 | |||||
| Common stock issuance for Securities Purchase Agreement | 444,444 | — | 1,541 | — | — | 1,541 | |||||
| Debt conversion to common stock | 11,824 | — | 321 | — | — | 321 | |||||
| Stock-based compensation | — | — | 49 | — | — | 49 | |||||
| Vesting of Restricted Stock Units | 1,298 | — | — | — | — | — | |||||
| Reverse stock split adjustment | 2,426 | — | — | — | — | — | |||||
| Distributions | — | — | — | — | (481) | (481) | |||||
| Net loss | — | — | — | (364) | (178) | (542) | |||||
| Balance at March 31, 2024 | 4,971,937 | $5 | $472,451 | $(409,437) | $16,993 | $80,012 | |||||
| Common stock received in sale of business | (5,060) | — | (30) | — | — | (30) | |||||
| Common stock issued for Employee Stock Purchase Plan | 2,061 | — | 14 | — | — | 14 | |||||
| Common stock issued for acquisition | 17,640 | — | 156 | — | — | 156 | |||||
| Stock-based compensation | — | — | (61) | — | — | (61) | |||||
| Reverse stock split adjustment | 690 | — | — | — | — | — | |||||
| Contributions | — | — | — | — | 301 | 301 | |||||
| Distributions | — | — | — | — | (1,380) | (1,380) | |||||
| Net income (loss) | — | — | — | (364) | 3,374 | 3,010 | |||||
| Balance at June 30, 2024 | 4,987,268 | $5 | $472,530 | $(409,801) | $19,288 | $82,022 | |||||
(Continued)
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Common Stock · Additional Paid-inCapital · Accumulated Deficit · NoncontrollingInterests · TotalEquity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (In thousands, except share data) · Shares · Amount | |||||||||||
| Balance at December 31, 2024 | 5,511,452 | $6 | $489,409 | $(356,976) | $56,094 | $188,533 | |||||
| Common stock issued for Employee Stock Purchase Plan | 1,161 | — | 40 | — | — | 40 | |||||
| Stock-based compensation | 422,091 | — | 23,252 | — | — | 23,252 | |||||
| Vesting of Restricted Stock Units | 15,835 | — | — | — | — | — | |||||
| Distributions | — | — | — | — | (7,364) | (7,364) | |||||
| Net income | — | — | — | 21,217 | 29,589 | 50,806 | |||||
| Balance at March 31, 2025 | 5,950,539 | $6 | $512,701 | $(335,759) | $78,319 | $255,267 | |||||
| Common stock issued for Employee Stock Purchase Plan | 866 | — | 65 | — | — | 65 | |||||
| Asset acquisition noncontrolling interest | — | — | — | — | 789 | 789 | |||||
| Debt conversion to common stock | 17,874 | — | 477 | — | — | 477 | |||||
| Stock-based compensation | 602,798 | 1 | 75,304 | — | — | 75,305 | |||||
| Vesting of Restricted Stock Units | 23,032 | — | — | — | — | — | |||||
| Contributions | — | — | 152 | — | 90 | 242 | |||||
| Distributions | — | — | — | — | (11,412) | (11,412) | |||||
| Net income (loss) | — | — | — | (17,697) | 33,841 | 16,144 | |||||
| Balance at June 30, 2025 | 6,595,109 | $7 | $588,699 | $(353,456) | $101,627 | $336,877 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.